ClinicalTrials.gg
RecruitingNCT05493605WIL-HEARTUpdated Oct 1, 2026

Cardiac Involvement in Wilson's Disease

An interventional study of Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope in Wilson's Disease, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.

Planned enrollment
2nd of 11
150 · median 40
Started
2023
with 2 others
No phase
8 of 17
3 open now
Registered
13th of 17
by date
Lead sponsor
7 of 17
Fondation Ophtalmologique Adolphe de Rothschild

Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 13th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hepatolenticular Degeneration with a site in France, or all of them as a file.
02

Study summary

Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.

03

Conditions studied

  • Wilson's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient with Wilson's disease confirmed by a Leipzig score ≥ 4
  • Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship
  • Member of or beneficiary of a Social Security scheme

Exclusion criteria

Exclusion Criteria:

  • Absolute or relative to MRI or contrast media
  • Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age
  • Patient with hepatic decompensation ( score stage C)
  • Patient in neuro-psychiatric decompensation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Cases

    The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).

    Procedure: Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope

Interventions

  • ProcedureDelivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope

    The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.

06

What researchers measure

Primary outcomes

  1. Contrast-enhanced cardiac MRI - Day 0

    Percentage of patients with abnormal contrast-enhanced cardiac MRI results

    Time frame: Day 0

  2. Contrast-enhanced cardiac MRI - Day 0

    Description of abnormalities (frequency and percentage)

    Time frame: Day 0

  3. Transthoracic echocardiography - Day 0

    Percentage of patients with abnormal transthoracic echocardiography results

    Time frame: Day 0

  4. Transthoracic echocardiography - Day 0

    Description of abnormalities (frequency and percentage)

    Time frame: Day 0

  5. Chest computed tomography scan without contrast - Day 0

    Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.

    Time frame: Day 0

  6. Electrocardiogram - Day 0

    Percentage of patients with abnormal electrocardiogram results

    Time frame: Day 0

  7. Electrocardiogram - Day 0

    Description of abnormalities (frequency and percentage)

    Time frame: Day 0

  8. Clinical examination - Day 0

    Percentage of patients with abnormal clinical examination

    Time frame: Day 0

  9. Clinical examination - Day 0

    Description of abnormalities (frequency and percentage)

    Time frame: Day 0

  10. Blood and urine tests - Day 0

    Percentage of patients with abnormal blood and urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria

    Time frame: Day 0

  11. Blood and urine tests - Day 0

    Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria

    Time frame: Day 0

  12. Lying and standing blood pressure tests - Day 0

    Percentage of patients with abnormal blood pressure tests results

    Time frame: Day 0

  13. Lying and standing blood pressure tests - Day 0

    Description of abnormalities (frequency and percentage)

    Time frame: Day 0

  14. Implantable loop recorder or ECG holter recorder- Day 21

    Percentage of patients with abnormal implantable loop record (or ECG holter record) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.

    Time frame: Day 21

  15. Implantable loop recorder or ECG holter recorder- Day 21

    Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.

    Time frame: Day 21

  16. Transthoracic echocardiography - Year 3

    Percentage of patients with abnormal transthoracic echocardiography results

    Time frame: Year 3

  17. Transthoracic echocardiography - Year 3

    Description of abnormalities (frequency and percentage)

    Time frame: Year 3

  18. Contrast-enhanced cardiac MRI - Year 3

    Percentage of patients with abnormal contrast-enhanced cardiac MRI results

    Time frame: Year 3

  19. Contrast-enhanced cardiac MRI - Year 3

    Description of abnormalities (frequency and percentage)

    Time frame: Year 3

  20. Chest computed tomography scan without contrast - Year 3

    Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.

    Time frame: Year 3

  21. Electrocardiogram - Year 3

    Percentage of patients with abnormal electrocardiogram results

    Time frame: Year 3

  22. Electrocardiogram - Year 3

    Description of abnormalities (frequency and percentage)

    Time frame: Year 3

  23. Clinical examination - Year 3

    Percentage of patients with abnormal clinical examination

    Time frame: Year 3

  24. Clinical examination - Year 3

    Description of abnormalities (frequency and percentage)

    Time frame: Year 3

  25. Blood and urine tests - Year 3

    Percentage of patients with abnormal blood or urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria

    Time frame: Year 3

  26. Blood and urine tests - Year 3

    Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria

    Time frame: Year 3

  27. Lying and standing blood pressure tests - Year 3

    Percentage of patients with abnormal blood pressure tests results

    Time frame: Year 3

  28. Lying and standing blood pressure tests - Year 3

    Description of abnormalities (frequency and percentage)

    Time frame: Year 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2023 (actual). Primary completion is estimated for Mar 2029, 72 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2026 → Mar 2029 and completion Mar 2026 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2022
First posted
Aug 9, 2022
StartActual
Mar 2, 2023
Primary completionEst.
Mar 2029was Mar 2026
CompletionEst.
Mar 2029was Mar 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2026→Mar 2029
Oct 1, 2026
Study completion
Mar 2026→Mar 2029
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Mar 2026→Mar 2029
    Study completion Mar 2026→Mar 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05493605
Responsible party
Sponsor
First posted
Aug 9, 2022
Start date
Mar 2, 2023
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Amélie YAVCHITZ
Contact
ayavhitz@for.paris
01 48 03 64 54
Aurélia POUJOIS
Contact
apoujois@for.paris
01 48 30 66 56

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion